POU6F2-AS2 (POU6F2 Antisense RNA 2)

News alerts, weekly reports and conference planners

almost3years

Long noncoding RNA POU6F2-AS2 contributes to the aggressiveness of nonsmall-cell lung cancer via microRNA-125b-5p-mediated E2F3 upregulation. (PubMed, Aging (Albany NY))

Thus, POU6F2-AS2 aggravates the oncogenicity of NSCLC by targeting the miR-125b-5p/E2F3 axis. Our findings suggest that POU6F2-AS2 is a novel therapeutic target for NSCLC.

almost 3 years ago

Journal

TCF3 (Transcription Factor 3) • E2F3 (E2F transcription factor 3) • POU6F2-AS2 (POU6F2 Antisense RNA 2)

3years

LncRNA POU6F2-AS2 contributes to malignant phenotypes and paclitaxel resistance by promoting SKP2 expression in stomach adenocarcinoma. (PubMed, J Chemother)

Based on RNA pull-down, cycloheximide and MG132 incubation experiments, POU6F2-AS2 promoted SKP2 by stabilizing NONO expression. In vitro and in vivo experiments have confirmed that the POU6F2-AS2/NONO/SKP2 axis promotes STAD progression, and that the silencing of POU6F2-AS2 plays a synergistic antitumour effect when combined with paclitaxel. Therefore, POU6F2-AS2 may be potentially developed as a target to inhibit STAD and reduce chemoresistance.

3 years ago

Journal

NONO (Non-POU Domain Containing Octamer Binding) • POU6F2-AS2 (POU6F2 Antisense RNA 2) • SKP2 (S-phase kinase-associated protein 2)

paclitaxel • MG132